This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BOEPPLE, P. A. Articles by CROWLEY, W. F. Search for Related Content PubMed PubMed Citation Articles by BOEPPLE, P. A. Articles by CROWLEY, W. F., Jr.

Use of a Potent, Long Acting Agonist of Gonadotropin-Releasing Hormone in the Treatment of Precocious Puberty^*

The Reproductive Endocrine Unit and the Vincent Memorial Laboratories, the Departments of Medicine, Gynecology, and the Children's Service, Massachusetts General Hospital Boston, Massachusetts 02114
The Divisions of Endocrinology and Adolescent and Young Adult Medicine, Department of Medicine, Children's Hospital, and Departments of Gynecology, Medicine, and Pediatrics, Harvard Medical School Boston, Massachusetts 02115

Correspondence: Address requests for reprints to: William F. Crowley, Jr., M.D., Reproductive Endocrine Unit, Massachusetts General Hospital, Fruit Street, Boston, Massachusetts 02114.

Abstract

STUDIES UTILIZING the administration of GnRH in various GnRH-deficient models have revealed the critical importance of the dose and mode of delivery of this releasing factor in determining the subsequent pituitary response. Chronic administration of long acting GnRH agonists (GnRHa), like continuous infusion of high doses of the native peptide, results in suppression of pituitary gonadotropin secretion. This selective and reversible suppression of gonadotropin secretion suggested several therapeutic applications for these analogs, particularly in the treatment of central precocious puberty (CPP), a disorder for which the previously available therapies lacked uniform efficacy and were associated with potential side effects.

Footnotes

^* This work was supported in part by NIH Grants HD-18169, RR-01066, RR-02172, and HD-07277.

This article has been cited by other articles:

				B. M. Windsor-Engnell, E. Kasuya, M. Mizuno, K. L. Keen, and E. Terasawa An increase in in vivo release of LHRH and precocious puberty by posterior hypothalamic lesions in female rhesus monkeys (Macaca mulatta) Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1000 - E1009. [Abstract] [Full Text] [PDF]

				L. Qi, T. M. Nett, M. C. Allen, X. Sha, G. S. Harrison, B. A. Frederick, E. D. Crawford, and L. M. Glode Binding and Cytotoxicity of Conjugated and Recombinant Fusion Proteins Targeted to the Gonadotropin-Releasing Hormone Receptor Cancer Res., March 15, 2004; 64(6): 2090 - 2095. [Abstract] [Full Text] [PDF]

				W.-H. Yang, M. Wieczorck, M. C. Allen, and T. M. Nett Cytotoxic Activity of Gonadotropin-Releasing Hormone (GnRH)-Pokeweed Antiviral Protein Conjugates in Cell Lines Expressing GnRH Receptors Endocrinology, April 1, 2003; 144(4): 1456 - 1463. [Abstract] [Full Text] [PDF]

				Is Obesity an Outcome of Gonadotropin-Releasing Hormone Agonist Administration? Analysis of Growth and Body Composition in 110 Patients with Central Precocious Puberty J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4480 - 4488. [Abstract] [Full Text]

				B. Kohn, J. R. Julius, and S. L. Blethen Combined Use of Growth Hormone and Gonadotropin-releasing Hormone Analogues: The National Cooperative Growth Study Experience Pediatrics, October 1, 1999; 104(4): 1014 - 1018. [Abstract] [Full Text]

				K. O. Klein, J. Baron, K. M. Barnes, O. H. Pescovitz, and G. B. Cutler Jr. Use of an Ultrasensitive Recombinant Cell Bioassay to Determine Estrogen Levels in Girls with Precocious Puberty Treated with a Luteinizing Hormone-Releasing Hormone Agonist J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2387 - 2389. [Abstract] [Full Text]

				M. R. Palmert, S. Radovick, and P. A. Boepple The Impact of Reversible Gonadal Sex Steroid Suppression on Serum Leptin Concentrations in Children with Central Precocious Puberty J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1091 - 1096. [Abstract] [Full Text]

				A. Barbazanges, P. V. Piazza, M. Le Moal, and S. Maccari Maternal Glucocorticoid Secretion Mediates Long-Term Effects of Prenatal Stress J. Neurosci., June 15, 1996; 16(12): 3943 - 3949. [Abstract] [Full Text] [PDF]

				R. D. Clemons, M. S. Kappy, T. E. Stuart, A. H. Perelman, and F. T. Hoekstra Long-term Effectiveness of Depot Gonadotropin-Releasing Hormone Analogue in the Treatment of Children With Central Precocious Puberty Arch Pediatr Adolesc Med, June 1, 1993; 147(6): 653 - 657. [Abstract] [PDF]

				P. J. Starceski, P. A. Lee, A. L. Albright, and C. J. Migeon Hypothalamic Hamartomas and Sexual Precocity: Evaluation of Treatment Options Arch Pediatr Adolesc Med, February 1, 1990; 144(2): 225 - 228. [Abstract] [PDF]

				M. S. Kappy, T. Stuart, and A. Perelman Efficacy of Leuprolide Therapy in Children With Central Precocious Puberty Arch Pediatr Adolesc Med, October 1, 1988; 142(10): 1061 - 1064. [Abstract] [PDF]